RONALD HUNT
CIK 1247851 · last filed 2026-02-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.91M
Companies
8
Total Filings
51
Lifetime Open-Market Net
$16.44M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLYB | Director | 249,239 | $16.16 | $4.03M | $4.00M | 10 | 2026-02-20 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 268,244 | $0.03 | $8.0K | $8.61M | 18 | 2025-01-23 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 13,224 | $23.01 | $304.3K | $20.00M | 17 | 2024-03-11 |
| STIM | Director | 1,543,962 | $1.87 | $2.89M | $0 | 2 | 2019-04-03 |
| Lite Strategy, Inc. (MEIP) Delisted | 10%+ Owner | 0 | $3.20 | $0 | -$25.28M | 1 | 2015-03-26 |
| Relypsa Inc (RLYP) Delisted | Director | 1,924,626 | — | — | $2.05M | 1 | 2013-11-20 |
| CDE | 10%+ Owner | 0 | $14.91 | $0 | $0 | 1 | 2012-08-06 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 3,028,439 | — | — | $7.06M | 1 | 2012-07-26 |
Recent Filings · Page 2 of 6
51 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-27 | Harpoon Therapeutics, Inc. (HARP) Delisted | Buy (P) | +1,543,500 | $0 | EDGAR |
| 2023-10-02 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +3,035 | $0 | EDGAR |
| 2023-10-02 | Iterum Therapeutics plc (ITRM) Delisted | Exer (M) | +5,479 | $0 | EDGAR |
| 2023-07-06 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +18,656 | $0 | EDGAR |
| 2023-07-03 | Iterum Therapeutics plc (ITRM) Delisted | Exer (M) | +2,796 | $0 | EDGAR |
| 2023-06-23 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2023-04-04 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +18,285 | $0 | EDGAR |
| 2023-04-03 | Iterum Therapeutics plc (ITRM) Delisted | Exer (M) | +2,041 | $0 | EDGAR |
| 2023-03-27 | Harpoon Therapeutics, Inc. (HARP) Delisted | Buy (P) | +10,000 | $10.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.